Lahore:The Department of Gastroenterology and Hepatology at The Children’s Hospital (Lahore), a Center of Excellence (COE) for the treatment of Lysosomal Storage Disorders (LSD), collaborated with Sanofi Pakistan to bring to Pakistan renowned international experts to address the rising incidence of LSDs in Pakistan and the way forward.
Addressing a press conference, Prof Huma Arshad Cheema Head, Department of Gastroenterology and Hepatology, The Children’s Hospital said: “LSDs are a group of rare inherited metabolic disorders. Children born of marriages within the family are at risk of these genetic diseases. According to the registry of the Children’s Hospital (Lahore), around 300 LSD patients have been diagnosed in the short span of 6 years but due to their critical condition almost a third of these patients lost their lives. 18 are currently on the charitable program of Sanofi Genzyme while some others are supported by other international charitable organizations.
She said despite this, 32 children have died in the last 12 months due to lack of treatment.
Director of Research, Consultant Internal Medicine, Emeritus Professor of Medicine, University of Cambridge, UK Prof Timothy M. Cox, Chief Executive Officer, International Gaucher Alliance (IGA), UK Tanya Collin-Histed, President, Lysosomal Storage Disorders (LSD) Society, Pakistan Atif Qureshi and Director External Affairs, Sanofi-aventis Pakistan Limited Laila Khan also spoke.
The panel lauded the ongoing efforts of Sanofi Genzyme and the Punjab government to provide relief to children suffering from LSDs but emphasized the need to address the primary issue of a lack of mechanism, policy or dedicated budget to fund therapy.
Currently, the Punjab government is funding the treatment of 23 patients; 2 patients are being funded by Sindh, 3 by the armed forces and 4 by private philanthropists.
Dr Huma Cheema appreciated the Punjab government for supporting the treatment of 23 patients on an ad-hoc basis while urging the government to consider the development of a policy with a dedicated budget.
For over 15 years, Sanofi Genzyme has been providing free of cost treatment to 18 LSD patients in Pakistan under its “Charitable Access Program” amounting to over PKR 300 million every year. Since 2013, Sanofi Genzyme has also been providing free-of-cost diagnostic support.
Tanya Collin-Histed, CEO of the International Gaucher Alliance, based in the UK, said “the majority of LSD patients diagnosed in Pakistan are of Gaucher Disease. The pathway to progress for patients and their families is through collaborative working by all stakeholders with the eventual aim of building an inclusive, sustainable health ecosystem.”
The press conference concluded with a plea from the experts for a rare disease policy, similar to Egypt.